Pfizer Quietly Chalks Up Another $2bn Year For Biosimilars

Bevacizumab And Trastuzumab Rivals Grow Ahead Of Adalimumab Launch

 
• By David Wallace
Two Billion Dollars $2bn Icon
For the second year running, Pfizer’s biosimilars sales exceeded $2bn • Source: Shutterstock

More from Biosimilars

More from Products